Cargando…
Depressed glutamate transporter 1 expression in a mouse model of Dravet syndrome
Dravet syndrome (DS) is a monogenic, often refractory, epilepsy resultant from SCN1A haploinsufficiency in humans. A novel therapeutic target in DS that can be engaged in isolation or as adjunctive therapy is highly desirable. Here, we demonstrate reduced expression of the rodent glutamate transport...
Autores principales: | Hameed, Mustafa Q., Hui, Benjamin, Lin, Rui, MacMullin, Paul C., Pascual‐Leone, Andres, Vermudez, Sheryl Anne D., Rotenberg, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502630/ https://www.ncbi.nlm.nih.gov/pubmed/37452008 http://dx.doi.org/10.1002/acn3.51851 |
Ejemplares similares
-
Transcranial magnetic stimulation tracks subminute changes in cortical excitability during propofol anesthesia
por: Gersner, Roman, et al.
Publicado: (2020) -
Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome
por: Wong, Jennifer C., et al.
Publicado: (2019) -
Drug repurposing for Dravet syndrome in scn1Lab
(−/−) mutant zebrafish
por: Sourbron, Jo, et al.
Publicado: (2019) -
Does long‐term phenytoin have a place in Dravet syndrome?
por: Zographos, George A., et al.
Publicado: (2022) -
Dravet syndrome
por: Incorpora, Gemma
Publicado: (2009)